Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2023; 29(18): 2784-2797
Published online May 14, 2023. doi: 10.3748/wjg.v29.i18.2784
Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
Eun Sil Kim, Ben Kang
Eun Sil Kim, Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, South Korea
Ben Kang, Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu 41944, South Korea
Author contributions: Kim ES contributed to the literature search, evidence procurement, writing and editing manuscript, revision; Kang B was the guarantor of the article, contributed to the literature search, evidence procurement, writing and editing manuscript, critical review of manuscript, revision and editing of final manuscript. All authors contributed to the article and approved the submitted version.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ben Kang, MD, PhD, Associate Professor, Department of Pediatrics, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, South Korea. benkang@knu.ac.kr
Received: December 28, 2022
Peer-review started: December 28, 2022
First decision: March 8, 2023
Revised: March 20, 2023
Accepted: April 17, 2023
Article in press: April 17, 2023
Published online: May 14, 2023
Processing time: 134 Days and 5.1 Hours
Core Tip

Core Tip: In pediatric Crohn’s disease (CD), the choice of biologic agents should be made more carefully to achieve the therapeutic goal. This review article focuses on comparing the efficacy of induction and maintenance of remission, safety profile, immunogenicity, preference, and compliance between infliximab and adalimumab in pediatric CD.